Carotid Doppler ultrasonographic findings of dapagliflozin use in type 2 diabetic patients

ÖNMEZ A., Gokosmanoglu F., Baycelebi G., ARIKAN A. A.

AGING MALE, vol.23, no.5, pp.1246-1250, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 23 Issue: 5
  • Publication Date: 2020
  • Doi Number: 10.1080/13685538.2020.1758657
  • Journal Name: AGING MALE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Abstracts in Social Gerontology, AgeLine, CINAHL, EMBASE, MEDLINE, SportDiscus
  • Page Numbers: pp.1246-1250
  • Keywords: Dapagliflozin, end-diastolic velocity, resistive index, carotid Doppler, type 2 diabetes, ENDOTHELIAL FUNCTION, METABOLIC SYNDROME, ARTERY, ATHEROSCLEROSIS, TESTOSTERONE, PARAMETERS, INHIBITORS, IMPACT, INDEX
  • Kocaeli University Affiliated: Yes


Aim: Sodium-glucose cotransporter 2 inhibitors have been shown to reduce the risk of cardiovascular disease in type 2 diabetes (T2DM) patients. The purpose of this study was to evaluate cardiovascular disease risk indirectly through Doppler ultrasonography (USG) of carotid artery vascular markers in T2DM patients using dapagliflozin. Methods: One hundred forty-five patients presenting to our clinic between March 2016 and June 2018 and diagnosed with T2DM were included in the study. These were divided into two groups - a dapagliflozin group of 85 patients and a 60-member non-dapagliflozin control group. Common carotid artery end-diastolic velocity (EDV), peak systolic velocity (PSV), and resistive index (RI) parameters were evaluated using Doppler USG in both groups. Results: The mean duration of follow-up was 2.2 +/- 0.4 years. Mean ages were 45 +/- 14 years in the dapagliflozin group and 42 +/- 15 in the control group. Mean HbA1c was 7.4 +/- 1.6 in the dapagliflozin group and 7.3 +/- 2.1 in the control group. Common carotid artery, PSV, and EDV parameters were higher (p = .012/p = .036), while RI was lower (p < .001), in the dapagliflozin group than in the control group. Conclusion: Vascular resistance was lower in the group using dapagliflozin for diabetes management.